Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any early-onset non-syndromic cataract in which the cause of the disease is a mutation in the CRYAB gene.
Features include always present findings: Posterior polar cataract; and sometimes findings: Developmental cataract and Retinal dystrophy. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Developmental cataract, Posterior polar cataract, Retinal dystrophy |
Age of onset: at birth.
CRYAB encodes crystallin alpha B (175 aa). May contribute to the transparency and refractive index of the lens. Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions. Highest expression in Heart Left Ventricle (1,863 TPM) and Brain Spinal cord cervical c-1 (1,663 TPM).
Cataract 16 multiple types is associated with mutations in the CRYAB gene on chromosome 11.
CRYAB is classified as a druggable target (Cell Surface category) with score 0.0.
Genetic testing for CRYAB is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature.
No clinical trials have been registered for cataract 16 multiple types.
10 publications have been identified in PubMed for cataract 16 multiple types. Research spans Clinical Trial Publication (30%), Basic Science / Preclinical (30%), and Review / Meta-Analysis (20%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 3 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:42 AM UTC
Online Mendelian Inheritance in Man
3 |
30% |
Research summaries | 2 | 20% |
Patient case studies | 1 | 10% |
Disease patterns and progression | 1 | 10% |
Mesquita R (2025). [PMID: 40725401](https://pubmed.ncbi.nlm.nih.gov/40725401/). *Genes (Basel)*. [Clinical Trial Publication]
Lungambi TM (2025). [PMID: 40474114](https://pubmed.ncbi.nlm.nih.gov/40474114/). *BMC Ophthalmol*. [Case Report / Case Series]
Yotsukura E (2025). [PMID: 41371979](https://pubmed.ncbi.nlm.nih.gov/41371979/). *BMJ Open Ophthalmol*. [Clinical Trial Publication]
Ogawa M (2025). [PMID: 39419841](https://pubmed.ncbi.nlm.nih.gov/39419841/). *Graefes Arch Clin Exp Ophthalmol*. [Epidemiology / Natural History]
Sankhe R (2025). [PMID: 41594547](https://pubmed.ncbi.nlm.nih.gov/41594547/). *Biomolecules*. [Basic Science / Preclinical]
Wang MY (2024). [PMID: 39648025](https://pubmed.ncbi.nlm.nih.gov/39648025/). *Zhonghua Yan Ke Za Zhi*. [Clinical Trial Publication]
Wei L (2024). [PMID: 39247380](https://pubmed.ncbi.nlm.nih.gov/39247380/). *Heliyon*. [Review / Meta-Analysis]
Liu Y (2024). [PMID: 39834393](https://pubmed.ncbi.nlm.nih.gov/39834393/). *Front Cell Dev Biol*. [Basic Science / Preclinical]
Baralić K (2024). [PMID: 38963141](https://pubmed.ncbi.nlm.nih.gov/38963141/). *Arh Hig Rada Toksikol*. [Basic Science / Preclinical]
Shiels A (2024). [PMID: 38927721](https://pubmed.ncbi.nlm.nih.gov/38927721/). *Genes (Basel)*. [Review / Meta-Analysis]